mirtazapine has been researched along with prazosin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| de Boer, TH; de Vos, CJ; Maura, G; Pinder, RM; Raiteri, M; Wieringa, J | 1 |
| de Boer, TH; Nefkens, F; van Delft, AM; van Helvoirt, A | 1 |
| Dlaboga, D; Dziedzicka-Wasylewska, M; Maj, J; Rogoz, Z; Wrobel, A | 1 |
| Imanishi, T; Inoue, T; Kakui, N; Kitamura, K; Koyama, T; Yamauchi, M; Yokoyama, F | 1 |
| Barbosa-Méndez, S; Matus-Ortega, M; Salazar-Juárez, A | 1 |
1 review(s) available for mirtazapine and prazosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for mirtazapine and prazosin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers.
Topics: Animals; Antidepressive Agents, Tricyclic; Autonomic Nervous System; Binding, Competitive; Cerebral Cortex; Corpus Striatum; In Vitro Techniques; Male; Mianserin; Mirtazapine; Norepinephrine; Prazosin; Quinuclidinyl Benzilate; Rats; Rats, Inbred Strains; Serotonin; Spiperone; Stereoisomerism; Synaptosomes; Yohimbine | 1988 |
Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Corpus Striatum; Dioxanes; Hippocampus; Idazoxan; Imidazoles; Male; Mianserin; Mirtazapine; Norepinephrine; Prazosin; Rats; Rats, Wistar; Serotonin; Tetrodotoxin | 1996 |
Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aggression; Animals; Antidepressive Agents, Tricyclic; Binding, Competitive; Cerebral Cortex; Exploratory Behavior; Male; Methoxamine; Mianserin; Mice; Mirtazapine; Phenylephrine; Prazosin; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1 | 2002 |
Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor.
Topics: Adrenergic alpha-Antagonists; Animals; Anti-Anxiety Agents; Conditioning, Classical; Fear; Male; Mianserin; Mirtazapine; Prazosin; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Adrenergic, alpha-1 | 2009 |
Synergistic interactions between mirtazapine and prazosin prevent the induction and expression of behavioral sensitization to cocaine in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Analysis of Variance; Anesthetics, Local; Animals; Cocaine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Locomotion; Male; Mianserin; Mirtazapine; Prazosin; Rats; Rats, Wistar | 2017 |